COVID-19 Virus Disease Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-blind, Monocenter, Phase II Trial to Assess the Efficacy of Calcium Dobesilate (CaD) vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.
The purpose of this study is to evaluate the efficacy and safety of CaD in reducing SARS-CoV-2 viral load in non-hospitalized adult patients diagnosed with COVID-19, documented with a positive SARS-CoV-2 PCR and with the occurrence of COVID-19 symptoms.
This study is a phase II, randomized, double-blind, placebo-controlled, monocenter trial. The study will assess the efficacy and safety of CaD compared to placebo in reducing SARS-CoV-2 viral load in non-hospitalized adult patients diagnosed with COVID-19, as well as monitoring symptoms severity, progression of the disease to severe form, and persistence of symptoms. The treatment period is seven consecutive days, followed by a 12-weeks observational period without treatment administration. Enrolled patients will be randomized, in a ratio of 1:1 into the following treatment groups: - IMP arm: patients will receive 2 x 2 capsules of Calcium Dobesilate (CaD) 500 mg (total of 2000 mg) daily for seven consecutive days - Placebo arm: patients will receive 2 x 2 capsules of matching placebo (Mannitol 500 mg) daily for seven consecutive days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04927442 -
Natural History Study of COVID-19 Using Digital Wearables
|
||
| Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
| Completed |
NCT04932850 -
Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.
|
Phase 1 | |
| Completed |
NCT04753762 -
Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection
|
||
| Recruiting |
NCT06259578 -
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
|
Early Phase 1 | |
| Withdrawn |
NCT05085574 -
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
|
Phase 2 | |
| Active, not recruiting |
NCT05077332 -
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
|
Phase 2 | |
| Terminated |
NCT05077969 -
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)
|
Phase 2 |